Actively Recruiting
Application of 18F-PSMA PET/CT Imaging in Prostate Specific Membrane Antigen Positive Tumors
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2024-12-27
400
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate the effectiveness of Al18F-PSMA-BCH PET/CT imaging in detecting tumors that express prostate specific membrane antigen (PSMA). The study focuses on patients with suspected or confirmed PSMA-positive tumors, including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, and multiple myeloma. It is a phase 2 interventional trial sponsored by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Participants will receive an intravenous injection of Al18F-PSMA-BCH followed by a PET/CT scan to assess tumor presence. This imaging procedure is the main intervention being studied, aiming to evaluate its tumor detection ability. The study does not include a comparison group or placebo, and there is no masking or blinding involved. During the study, participants will undergo the PET/CT scan after the tracer injection, and researchers will measure the diagnostic value of the imaging over approximately one year. Participants must be willing to cooperate with all study procedures and provide informed consent. Safety and diagnostic outcomes will be monitored throughout the study period, which is expected to complete by October 2025.
CONDITIONS
Brief Title
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with suspected or clearly diagnosed PSMA positive-expressing tumors, including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.
- Age is 18 or older; No gender limitation.
- Signed the informed consent.
- Willing and able to cooperate with all projects in this study.
You will not qualify if you...
- Patients with serious neurological diseases, or gastrointestinal tract disease, cardiovascular disease, liver disease, kidney disease, blood system disease, endocrine system disease, respiratory system disease, immune deficiency disease, etc.
- Claustrophobia.
- Pregnant or lactation women.
- Received experimental drug or device within 1 month.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants receive an intravenous injection of Al18F-PSMA-BCH and undergo PET/CT imaging to evaluate tumor detection efficacy.
1 visit (in-person)
Duration - Up to 1 year
Participants are monitored for approximately 1 year to assess the diagnostic value of the imaging procedure.
Follow-up visits as needed
Trial Site Locations
Total: 1 location
1
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Chaoyang, China, 100029
Actively Recruiting
Research Team
X
Xin Cheng, MD
G
Guozhu Hou, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here